Evidence from the studies included in this systematic review did not demonstrate that vitamin D supplementation in adults , results in an improvement in circulating inflammatory and endothelial function biomarkers/parameters .
This systematic review does not therefore support the use of vitamin D supplementation as a therapeutic or preventative measure for CVD in this respect
This systematic review aims to evaluate r and omised controlled trials ( RCTs ) investigating the effect of vitamin D supplementation on  endothelial function and inflammation in adults .
Effects of high-dose cholecalciferol on serum markers of inflammation and immunity in patients with early chronic kidney disease
Background / objectives : Vitamin D has anti-inflammatory and immune-regulating properties . We aim ed to determine if high-dose cholecalciferol supplementation for 1 year in subjects with early chronic kidney disease ( CKD ) improved circulating markers of inflammation and immunity . Subjects/ methods : In this double-blind , r and omized , placebo-controlled trial , 46 subjects with early CKD ( stages 2 and 3 ) were supplemented with oral cholecalciferol ( 50 000 IU weekly for 12 weeks followed by 50 000 IU every other week for 40 weeks ) or a matching placebo for 1 year . Serum tumor necrosis factor-α , interleukin-6 , monocyte chemoattractant protein-1 ( MCP-1 ) , interferon gamma-induced protein-10 and neutrophil gelatinase-associated lipocalin were measured at baseline , 12 weeks and 1 year . Serum cathelicidin ( LL-37 ) was measured at baseline and 12 weeks . An in vitro experiment was performed to investigate the effect of 1,25-dihydroxyvitamin D3 ( 1,25(OH)2D3 ) treatment on MCP-1 secretion in THP-1 monocytes activated with lipopolysaccharide ( LPS ) and Pseudomonas aeruginosa . Results : By 12 weeks , serum MCP-1 decreased in the cholecalciferol group ( 66.2±2.5 to 60.8±2.6 pg/ml , group-by-time interaction P=0.02 ) but was not different from baseline at 1 year . Other markers of inflammation and immunity did not change . In vitro , LPS- and Pseudomonas-activated monocytes treated with 1,25(OH)2D3 had significantly less MCP-1 secretion compared with untreated cells . Conclusions : High-dose cholecalciferol  decreased serum MCP-1 concentrations by 12 weeks in patients with early CKD , although the decrease was not maintained for the remainder of the year . In vitro results confirm an MCP-1-lowering effect of vitamin D. Future studies should determine if vitamin D-mediated reductions in MCP-1 concentrations reflect improved clinical outcomes
Evidence from the studies included in this systematic review did not demonstrate that vitamin D supplementation in adults , results in an improvement in circulating inflammatory and endothelial function biomarkers/parameters .
This systematic review does not therefore support the use of vitamin D supplementation as a therapeutic or preventative measure for CVD in this respect
This systematic review aims to evaluate r and omised controlled trials ( RCTs ) investigating the effect of vitamin D supplementation on  endothelial function and inflammation in adults .